Akorn (AKRX) Issues Weak FY12 EPS, Revs Outlook
Tweet
Share
E-mailGet Alerts AKRX Hot Sheet
Price: $0.09 --0%
Financial Fact:
Amortization of intangibles: 16.47M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Amortization of intangibles: 16.47M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Akorn, Inc. (Nasdaq: AKRX), has provided full year 2012 financial guidance. The Company’s guidance includes the expected impact of the recent product acquisition from H. Lundbeck A/S, but excludes any impact of the pending acquisition of certain assets from Kilitch Drugs (India) Limited, as well as the impact from any products for which the company has not yet received FDA approval. The Company will provide a more detailed update during its year-end 2011 conference call.
Revs: $210 - $220 million
Adjusted EPS: 42 - 45 cents.
The Street is modeling revs of $221.1 million and EPS of 45 cents.
Revs: $210 - $220 million
Adjusted EPS: 42 - 45 cents.
The Street is modeling revs of $221.1 million and EPS of 45 cents.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- Full Truck Alliance (YMM) Tops Q2 EPS by 10c; beats on guidance
- Ocean Power Technologies revises fiscal 2026 results after audit
Create E-mail Alert Related Categories
Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
